Results from a clinical trial of eteplirsen, a drug designed to treat Duchenne muscular dystrophy, suggest that the therapy allows participants to walk farther than people treated with placebo and dramatically increases production of a protein vital to muscle growth and health.
The study, led by a team in The Research Institute at Nationwide Children’s Hospital, is the first of its kind to show these results from an exon-skipping drug—a class of therapeutics that allows cells to skip over missing parts of the gene and produce protein naturally.
“I’ve been doing this for more than 40 years and this is one of the most exciting developments we’ve seen,” says Jerry Mendell, MD, lead author of the study and director of the Center for Gene Therapy at Nationwide Children’s. “It offers great hope to patients with and their families.”
The research, which appears online Aug. 1 in the journal Annals of Neurology, is the first study from a double-blind controlled randomized trial of an exon-skipping agent to provide conclusive proof based on the standard six-minute walk test used to measure muscle function in patients with Duchenne muscular dystrophy (DMD), the most common form of muscular dystrophy in children.
About one in every 5,000 male births in the U.S. has the disorder, which usually leaves patients unable to walk on their own by age 12. Children with DMD have a mutation that cripples the body’s ability to produce a protein called dystrophin, which helps absorb the shock or energy that’s created when a muscle contracts. Without it, that released energy injures muscle fibers. Over time, the muscle degenerates, scar tissue builds up and fat slowly replaces the dead muscle.
The exact mutation varies from patient to patient but in 65 percent of cases, the dystrophin gene is missing large sections of DNA called exons, which carry the instructions for protein production. Accompanying this type of mutation is a spontaneously occurring reaction that enables muscle cells to skip over the deleted sections and produce smaller—but functional—versions of protein.
Eteplirsen, manufactured by Sarepta Therapeutics in Cambridge, Mass., mimics this naturally occurring phenomenon, allowing cells to skip over exon 51 in the dystrophin gene. About 13 percent of patients with the disorder have this mutation. Nationwide Children’s began the phase II trial of eteplirsen in August 2011, enrolling 12 boys age 7 to 12 years.
Participants received the drug via weekly IVs, with one group getting a 30 mg/kg dose and another group receiving 50 mg/kg. A control group received a placebo. Participants completed a six-minute walk test at the outset and again at weeks 12, 24 and 48. Muscle biopsies were also taken when the study began and again at those intervals to measure for dystrophin-positive muscle fibers.
Although there was no dystrophin production at 12 weeks, participants showed a 23 percent increase in dystrophin-positive muscle fibers by the 24-week mark. The striking improvement and lack of side effects prompted researchers to switch participants in the placebo group to the drug. By week 48, participants had a 52 percent increase in dystrophin-positive muscle fibers and were able to walk 67.3 meters farther than the placebo group on the six-minute walk test.
Although the results are promising, Dr. Mendell is quick to note that the small study leaves many questions unanswered.
The Latest Bing News on:
Duchenne Muscular Dystrophy
- Rabbi Yosef Zvi Rimon: Influencing the fate of millions with muscular dystrophyon May 10, 2024 at 6:15 am
O ne Saturday night while Rabbi Yosef Zvi Rimon was teaching a group of seminary students at his house in Alon Shvut, there was a knock at the door. Tentatively, he opened it and
- ASGCT 2024: Kate Therapeutics Unveils Gene Therapy Platform and Product Pipeline Progresson May 9, 2024 at 7:00 am
KateTx debuted less than a year ago with a $51 million Series A round co-led by Westlake Village BioPartners and Versant Ventures.
The Latest Google Headlines on:
Duchenne Muscular Dystrophy
[google_news title=”” keyword=”Duchenne Muscular Dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Duchenne Muscular Dystrophy treatment
- My Turn | Illinois can lead the way in the fight for a cure to Duchenne Muscular Dystrophyon May 7, 2024 at 2:45 am
"Knowing that both of our sons have what is essentially a death sentence was and is devastating," writes Daniel Flessner of Roberts.
- Duchenne Muscular Dystrophy: the global clinical trials landscape 2024on April 29, 2024 at 4:00 am
Clinical trials across the globe are investigating new treatments for Duchenne Muscular Dystrophy, improving muscular and skeletal health.
- Duchenne Muscular Dystrophy: the global clinical trials landscape 2024on April 29, 2024 at 12:02 am
Impacting approximately 1 in 5,000 males globally, Duchenne Muscular Dystrophy is a rare genetic disorder characterised by progressive muscle weakness and skeletal degeneration. The prevalence of ...
- Duchenne Muscular Dystrophyon April 28, 2024 at 5:00 pm
Rome, MD, MPH, examined how the FDA’s accelerated approval process has moved 5 genetically targeted treatments for Duchenne muscular dystrophy (DMD) through its pipeline despite limited evidence ...
- Ineffective Treatment of Muscular Dystrophy with an Anabolic Steroid and Other Measureson April 28, 2024 at 5:00 pm
9 The period of treatment was twelve months ... He believed that the underlying molecular defect in Duchenne muscular dystrophy was affected by physical activity which hastened the deterioration ...
- Duchenne UK and Parent Project Muscular Dystrophy Award $500,000 to Evaluate Safety and Tolerability of Muscle Progenitor Cells in Phase 1 Trialon April 23, 2024 at 3:00 am
WASHINGTON, April 23, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization, and the UK charity Duchenne ... and more effective treatments reach the clinic.
- My son's smile gives me hope for Duchenne muscular dystrophy. A new law could help otherson April 22, 2024 at 10:01 pm
Finally, when we were approved for evaluation, we received a devastating diagnosis: Duchenne muscular dystrophy ... 1 in the first trial for a Duchenne treatment. We considered ourselves the ...
- An FDA pathway can accelerate innovation for Duchenne muscular dystrophyon April 21, 2024 at 5:00 pm
Charlie has Duchenne muscular dystrophy, a degenerative genetic disease ... in following scientific data and reason to approve new treatments by using the accelerated approval program, beginning ...
- Possible Pulmonary Benefit With Viltolarsen for Duchenne Muscular Dystrophyon April 15, 2024 at 5:00 pm
Duchenne muscular dystrophy is incurable ... experienced mild-to-moderate treatment-emergent adverse events (TEAEs), and four events were considered treatment-related. There were no serious ...
- Parent Project Muscular Dystrophy Launches First State-Specific Duchenne Advocacy Day in Illinoison April 14, 2024 at 5:00 pm
Parent Project Muscular Dystrophy (PPMD ... We invest deeply in treatments for this generation of Duchenne patients and in research that will benefit future generations. Our advocacy efforts ...
The Latest Google Headlines on:
Duchenne Muscular Dystrophy treatment
[google_news title=”” keyword=”Duchenne Muscular Dystrophy treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]